[New paper] Reversion of BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitors in breast cancer
Our new paper has been published in iScience.
In this paper, we conducted genomic analyses using PDX models and cell lines from breast cancer patients with the BRCA1 L1780P mutation and identified that reversion mutations confer resistance to PARP and ATM inhibitors.
Congratulations!
Se-Young Jo. et al. Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer. iScience. Volume 27 Issue 8 2024. doi: 10.1016/j.isci.2024.110469.
Collaboration with Jeong Dong Lee and Hyung Seok Park

Commentaires